Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1

Lars Erik Kristensen, Ahmed M Soliman, Kim Papp, Douglas White, Lisa Barcomb, Wenjing Lu, Ann Eldred, Frank Behrens, Lars Erik Kristensen, Ahmed M Soliman, Kim Papp, Douglas White, Lisa Barcomb, Wenjing Lu, Ann Eldred, Frank Behrens

Abstract

Objectives: PsA is a heterogeneous disease that impacts many aspects of social and mental life, including quality of life. Risankizumab, an antagonist specific for IL-23, is currently under investigation for the treatment of adults with active PsA. This study evaluated the impact of risankizumab vs placebo on health-related quality of life (HRQoL) and other patient-reported outcomes (PROs) among patients with active PsA and inadequate response or intolerance to conventional synthetic DMARD (csDMARD-IR) in the KEEPsAKE 1 trial.

Methods: Adult patients with active PsA (n = 964) were randomized (1:1) to receive risankizumab 150 mg or placebo. PROs assessed included the 36-Item Short-Form Health Survey (SF-36, v2), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), EuroQoL-5 Dimension-5 Level (EQ-5D-5L), Patient's Assessment of Pain, Patient's Global Assessment (PtGA) of Disease Activity, and Work Productivity and Activity Impairment-PsA (WPAI-PsA) questionnaire. Least squares (LS) mean change from baseline at week 24 was compared between risankizumab and placebo.

Results: At week 24, differences between groups were observed using LS mean changes from baseline in SF-36 physical component summary and mental component summary; FACIT-Fatigue; EQ-5D-5L; Patient's Assessment of Pain; PtGA; all eight SF-36 domains (all nominal P < 0.001); and the WPAI-PsA domains of impairment while working (presenteeism), overall work impairment and activity impairment (all nominal P < 0.01).

Conclusion: Risankizumab treatment resulted in greater improvements in HRQoL, fatigue, pain and work productivity in patients with active PsA who have csDMARD-IR, when compared with placebo.

Trial registration: ClinicalTrials.gov, https://ichgcp.net/clinical-trials-registry/NCT03675308" title="See in ClinicalTrials.gov">NCT03675308.

Keywords: DMARDs; biological therapies; outcome measures; patient attitude to health; quality of life; spondyloarthropathies (including psoriatic arthritis).

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Figures

Fig . 1
Fig. 1
LS mean change and difference (95% CI) in SF-36 component summary and domain scores from baseline at week 24 aNominal P < 0.001 for risankizumab vs placebo. BP: bodily pain; GH: general health; LS: least squares; MCS: mental component summary; MH: mental health; PBO: placebo; PCS: physical component summary; PF: physical health; RE: role emotional; RZB: risankizumab; RP: role physical; SF: social functioning; SF-36: 36-Item Short-Form Survey; VT: vitality.
Fig . 2
Fig. 2
LS mean change and difference (95% CI) in WPAI-PsA domain scores from baseline at week 24 aReported only for patients who were employed. bNominal P < 0.001 for risankizumab vs placebo. cNominal P < 0.01 for risankizumab vs placebo. LS: least squares; PBO: placebo; RZB: risankizumab; WPAI-PsA: Work Productivity and Activity Impairment.

References

    1. Duarte GV, Faillace C, de Carvalho JF.. Psoriatic arthritis [review] . Best Pract Res Clin Rheumatol 2012;26:147–56.
    1. Gladman DD, Chandran V.. Observational cohort studies: lessons learnt from the University of Toronto psoriatic arthritis program [review] . Rheumatology 2011;50:25–31.
    1. Lee S, Mendelsohn A, Sarnes E.. The burden of psoriatic arthritis: a literature review from a global health systems perspective. Pharm Ther 2010;35:680.
    1. Kristensen LE, Englund M, Neovius M. et al. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study. Ann Rheum Dis 2013;72:1675–9.
    1. Kristensen LE, Jorgensen TS, Christensen R. et al. Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann Rheum Dis 2017;76:1495–501.
    1. Strand V, Sharp V, Koenig AS. et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012;71:1143–50.
    1. Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W.. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009;7:1–12.
    1. Gudu T, Gossec L.. Quality of life in psoriatic arthritis [review] . Expert Rev Clin Immunol 2018;14:405–17.
    1. Ogdie A, Coates LC, Gladman DD.. Treatment guidelines in psoriatic arthritis [review] . Rheumatology 2020;59:i37–i46.
    1. Singh JA, Guyatt G, Ogdie A. et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol 2019;71:5–32.
    1. Mease PJ, McInnes IB, Tam L-S. et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology 2021;60:2109–21.
    1. Saber TP, Ng C, Renard G. et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010;12:R94–6.
    1. Perrotta FM, Marchesoni A, Lubrano E.. Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol 2016;43:350–5.
    1. Gossec L, McGonagle D, Korotaeva T. et al. Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature [review] . J Rheumatol 2018;45:6–13.
    1. Iwakura Y, Nakae S, Saijo S, Ishigame H.. The roles of IL‐17A in inflammatory immune responses and host defense against pathogens [review]. Immunol Rev 2008;226:57–79.
    1. Augustin M, Lambert J, Zema C. et al. Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials. JAMA Dermatol 2020;156:1344–53.
    1. Blauvelt A, Leonardi CL, Gooderham M. et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol 2020;156:649–58.
    1. Gordon KB, Strober B, Lebwohl M. et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018;392:650–61.
    1. Kristensen LE, Keiserman M, Papp K. et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 keepsake 1 trial. Ann Rheum Dis 2022;81:225–31.
    1. Östör A, Van den Bosch F, Papp K. et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 keepsake 2 trial. Ann Rheum Dis 2022;81:351–8.
    1. Mease P, Kellner H, Morita A. et al. Op0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. Ann Rheum Dis 2018;77:200–1.
    1. Ware JE Jr, Sherbourne CD.. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:473–83.
    1. Ware J, Kosinski M, Keller S.. SF-36 physical and mental health summary scales: a user's manual. Boston, MA: Health Assessment Lab, New England Medical Center, 1994.
    1. Ware J, Kosinski M, Keller S.. SF-36. Health survey: manual and interpretation guide. Boston, MA: Health Assessment Lab, New England Medical Center, 1993.
    1. Chandran V, Bhella S, Schentag C, Gladman DD.. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 2007;66:936–9.
    1. Luo N, Cheung YB, Ng R, Lee CF.. Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores? Health Qual Life Outcomes 2015;13:1–9.
    1. Herdman M, Gudex C, Lloyd A. et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36.
    1. Hawker GA, Mian S, Kendzerska T, French M.. Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), McGill pain questionnaire (MPQ), short‐form McGill pain questionnaire (SF‐MPQ), chronic pain grade scale (CPGS), short form‐36 bodily pain scale (SF‐36 BPS), and measure of intermittent and constant osteoarthritis pain (icoap) [review] . Arthritis Care Res 2011;63:S240–52.
    1. Nikiphorou E, Radner H, Chatzidionysiou K. et al. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature [review] . Arthritis Res Ther 2016;18:1–11.
    1. Felson DT, Anderson JJ, Boers M. et al. The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729–40.
    1. Reilly Associates. WPAI translations. (14 March 2022, date last accessed).
    1. Reilly MC, Zbrozek AS, Dukes EM.. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353–65.
    1. Strand V, Mease PJ, Soriano ER. et al. Improvement in patient-reported outcomes in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from select-PSA 1. Rheumatol Ther 2021;8:1789–808.
    1. Ogdie A, De Wit M, Duffin KC. et al. Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT working group. J Rheumatol 2017;44:697–700.
    1. McInnes IB, Rahman P, Gottlieb AB. et al. Efficacy and safety of guselkumab, an interleukin‐23p19-specific monoclonal antibody, through one year in biologic‐naive patients with psoriatic arthritis. Arthritis Rheum 2021;73:604–16.
    1. Deodhar A, Helliwell PS, Boehncke W-H. et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020;395:1115–25.
    1. Ogdie A, Michaud K, Nowak M. et al. Patient’s experience of psoriatic arthritis: a conceptual model based on qualitative interviews. RMD open 2020;6:e001321.
    1. Kavanaugh A, Marzo-Ortega H, Vender R. et al. Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-p2 results to 52 weeks. Clin Exp Rheumatol 2019;37:566–74.
    1. Strand V, de Vlam K, Covarrubias-Cobos JA. et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open 2019;5:e000808.
    1. Kavanaugh A, Gottlieb A, Morita A. et al. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis 2019;78:1215–9.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する